The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001060336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
9/04/2026
Date registered
Help: Date registered
27/08/2026
Date last updated
Help: Date last updated
3/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
27/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A phase II clinical trial to assess safety and efficacy of personalised mRNA vaccine for children and young adults with high-risk brain tumours
Scientific title
Multicentre, investigator-initiated phase II clinical trial to assess safety and efficacy of personalised mRNA vaccine targeting tumour-associated neoantigens in children and young adults with high-risk brain tumours: the PaedNeoVax study
Additional trial identifiers [1] 316587 0
None
Universal Trial Number (UTN)
Trial acronym
PaedNeoVax
Related trial records

Health condition
Health condition(s) studied:
Brain Cancer 340767 0
Condition category
Condition code
Cancer 336949 336949 0 0
Brain
Cancer 336950 336950 0 0
Children's - Brain

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
PTX-108 is a personalised mRNA anti-tumour vaccine designed for the treatment of young patients with brain cancer. The vaccine comprises an individualised mRNA sequence encapsulated in a common lipid nanoparticle. The personalised vaccine is generated from a participant's neoantigens and tumour-associated antigens. This phase II clinical trial will investigate the safety and efficacy of the personalised PTX-108 mRNA cancer vaccine in paediatric and young adult patients with high-risk brain tumours including relapsed or refractory high-grade tumours and patients with newly diagnosed Diffuse Midline Glioma (DMG) following completion of radiation therapy.

Phase II will be a stratified expansion phase. Phase II Stratum A will include patients with newly diagnosed DMG, with outcomes compared to matched historical cohorts from the international DIPG Registry (iDIPGR), who were diagnosed after 2010, and have genomic, clinical and survival data available. Phase II Stratum B will include patients with other high-risk or relapsed/refractory brain tumours, with outcomes analysed descriptively. Stratum B is descriptive statistics only. As paediatric brain tumours can have significantly different disease trajectories and timelines to progression, the time-to-event outcomes (progression-free survival and overall survival) will depend on the characteristics of the participants enrolled into Stratum B. As the tumour types and clinical characteristics of the enrolled population cannot be predicted in advance, the appropriate descriptors and analyses will be adapted as the Stratum B population is established and further understood.

The vaccine will be given into the muscle, either in the upper arm or the thigh, depending on what is most suitable for the participant. Phase II dose will be determined during phase I of the study. Phase I is described in a separate entry within the registry.

The total duration of therapy will be around 26 weeks. Adherence is assessed through directly observed administration of the vaccine by qualified staff during scheduled in-clinic visits, with detailed documentation of attendance and dose administration in study records. The study pharmacist will administer the vaccine.

Participants in both strata will receive the same doses and follow the same dose schedule, they will receive 9 doses of personalised mRNA vaccine at the RP2D established in Phase I. In case of dose modifying toxicities DMT, PTX-108 vaccine dose de-escalation will be done as per the following:
Dose level 0: 200 micrograms
Dose level -1: 100 micrograms
Dose level -2: 50 micrograms

The dose schedule is described below:

Dose 1:
Administered on Day 1

Dose 2:
Administered on Day 10

Dose 3:
Administered on Day 24

Dose 4:
Administered on Day 38

Dose 5:
Administered on Day 52

Dose 6:
Administered on Day 66

Dose 7:
Administered on Day 80

Dose 8:
Administered on Day 94

Dose 9 (Booster):
Administered on Day 180 - 190
Intervention code [1] 333272 0
Treatment: Drugs
Description of the comparator or control
In Phase II Stratum A participants will be compared with a matched historical cohort of patients from the international DMG Registry, iDIPGR (https://www.dipgregistry.org) at 12 and 24 months after commencement of therapy. These matched controls will be taken from participants registered in the iDIPGR who were diagnosed after 2010 (January 2010 to January 2026), and have genomic, clinical and survival data available.
Control group
Historical

Outcomes
Primary outcome [1] 344471 0
Stratum A: Progression-free survival (PFS) and overall survival (OS) will be assessed as a composite outcome in patients with newly diagnosed DMG
Timepoint [1] 344471 0
12 and 24 months after start of therapy
Primary outcome [2] 344472 0
Stratum B: PFS and OS will be assessed as a composite outcome in patients with high risk or relapsed brain tumours
Timepoint [2] 344472 0
12 and 24 months after start of therapy
Secondary outcome [1] 458698 0
Tumour-derived neoantigens and tumour-associated antigens (TAAs) assessed as a composite outcome
Timepoint [1] 458698 0
Study Completion, at 24 months after study enrolment
Secondary outcome [2] 458699 0
To evaluate the radiographic objective response rate (ORR), defined as the sum of complete responses (CR) and partial responses (PR), using disease specific guidelines.
Timepoint [2] 458699 0
12 and 24 months after start of therapy.
Secondary outcome [3] 458700 0
Feasibility of vaccine design and administration within 3 months of enrolment, this will be assessed as a composite outcome
Timepoint [3] 458700 0
Reviewed at every participant's first dose

Eligibility
Key inclusion criteria
Each participant (Stratum A or Stratum B) must meet all the following criteria to be enrolled in this trial:

Age: Participant must be between 6 months and 25 years at the time of enrolment.


Histological confirmation of one of the following high risk central nervous system tumours (either at initial diagnosis or relapsed/refractory disease):
- Any relapsed/refractory WHO grade 3 or 4 central nervous system tumour
- Newly diagnosed diffuse midline glioma in a patient anticipated to be able to start study therapy within 20 weeks post biopsy
- Newly diagnosed high risk medulloblastoma, ependymoma, or other high-risk brain tumour after discussion with the study chairs (includes p53-mutant SHH medulloblastoma, PFA ependymoma with 6q deletion and/or 1q gain or other high risk molecular alterations associated with less than 20% anticipated 5 year survival) who are anticipated to be able to proceed to PTX-108 therapy after completion of institutional standard-of-care treatment.


Co-enrolment on the Zero Childhood Cancer (ZERO) molecular profiling platform (repeat tumour sampling in relapsed patients to obtain a current representative sample), with successful tumour WGS +/- RNA-seq analysis with a requirement of at least five potential neoantigens or tumour-associated antigens (TAAs) for vaccine production.


Informed consent as demonstrated by a signed and dated informed consent form completed by the participant or a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant’s behalf.




For a participant to commence personalised PTX-108 vaccine therapy (Reassessment), participants must be re-screened within 7 days of anticipated treatment start date (28 days for imaging) and the following criteria must be met:

- Confirmation of individualised PTX-108 vaccine available at the treating site for the participant.

- Measurable disease as per RAPNO/RANO 2.0 criteria (any previously irradiated lesion needs to have progressed since prior radiation therapy except for participants with newly diagnosed DMG and other high-risk brain tumours proceeding to vaccine therapy after completion of standard frontline therapy). Newly diagnosed patients eligible for study otherwise without measurable disease can be enrolled on review with the study team.

- Lansky/Karnofsky performance score of greater than 50. Use Karnofsky for patients over 16 years of age and Lansky for patients less than 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

- Life expectancy of at least 12 weeks at the time of re-screening. No clinical or radiological evidence of brain herniation or significant mass effect resulting in risk of imminent neurological deterioration.

- Prior therapy: Patients must have fully recovered from prior anti-cancer therapy including
~Myelosuppressive chemotherapy: Greater than 21 days between prior myelosuppressive therapy and PTX-108 commencement (or more than 42 days since last dose of nitrosourea).
~Non-myelosuppressive anticancer agents: greater than 7 days after the last dose.
~Immunotherapy: greater than 42 days after the last dose
~Monoclonal antibodies: greater than 21 days after the last dose.
~Radiation therapy: greater than 4 weeks after completion of radiation including CSI but within 12 weeks of biopsy for those patients with newly diagnosed DMG.

- Haematopoietic growth factor: greater than 14 days for long acting (peg-filgrastim) or greater than 7 days for short acting growth factor.

- Adequate haematologic function defined as:
~Haemoglobin greater than or equal to 80 g/L (post transfusion permitted)
~Absolute Neutrophil Count (ANC) greater or equal to 1.0 x109/L
~Absolute Lymphocyte Count greater or equal to 1.0 x109/L
~Platelet count greater or equal to 75 x109/L (cannot be post-transfusion)

- Adequate renal function defined as:
~Serum creatinine = Less than 1.5x institutional upper limit of normal (ULN) for age and sex

- Adequate liver function defined as:
~Total bilirubin = Less than 1.5 x upper limit of normal (ULN) for age
~AST and ALT = Less than 5 x upper limit of normal (ULN) for age
~Adequate coagulation (INR, PT and aPTT = 1.5 times ULN)

Investigator confirmation that the participant has no other serious medical conditions which are considered by the investigator to unacceptably increase the risk to the participant
Minimum age
6 Months
Maximum age
25 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion Criteria for Study Enrolment:

Known hypersensitivity to mRNA vaccines

Pregnant and breastfeeding females

Underlying congenital immunodeficiency



Exclusion Criteria for Vaccine Therapy:

Administration of live vaccine within 4 weeks of planned vaccine therapy commencement

Pregnant and breastfeeding females

No current corticosteroid therapy other than physiologic replacement doses equivalent to hydrocortisone maximum 20mg/m2/day

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase II Stratum A: Single-arm cohort of newly diagnosed DMG participants who are able to commence study therapy within 20 weeks of biopsy. Outcomes will be compared with a matched historical cohort from the international DIPG Registry (iDIPGR), with participants further evaluated according to PBMC T-cell-specific response.

Phase II Stratum B: Single-arm cohort with no comparator group, comprising newly diagnosed high-risk medulloblastoma, ependymoma or other high-risk brain tumours, and participants with refractory or recurrent brain tumours (including progressive DMG) who have not previously received PTX-108 on this study. Outcomes will be analysed descriptively.
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
It was estimated that the sample size would be approximately 65 participants in Phase II with 45 included in the stratum A (newly diagnosed DMG) based on the expected number of eligible participants who were likely to consent to the study across the study sites over the three-year recruitment period. 65 participants would provide us the ability to evaluate grade 3 or higher TEAEs and/or treatment termination due to DLT occurring in 30% of participants to within +/-11% precision. Given an expected immunologic response in 50% of stratum A participants, 23 stratum A participants and 45 matched international DIPG Registry (iDIPGR) controls would provide 80% power to detect an increase in the probability of survival at 12 months from 50% to 86% (hazard ratio of 0.22) with a 5% type I error rate in DMG. These matched controls will be taken from participants registered in the iDIPGR who were diagnosed after 2010, and have genomic, clinical and survival data available.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC

Funding & Sponsors
Funding source category [1] 321205 0
Government body
Name [1] 321205 0
Australian Department of Health and Aged Care, Medical Research Future Fund (MRFF)
Country [1] 321205 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Australian and New Zealand Children's Haematology Oncology Group
Address
Country
Australia
Secondary sponsor category [1] 324045 0
None
Name [1] 324045 0
none
Address [1] 324045 0
Country [1] 324045 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319733 0
Women's and Children's Health Network Human Research Ethics Committee
Ethics committee address [1] 319733 0
Ethics committee country [1] 319733 0
Australia
Date submitted for ethics approval [1] 319733 0
24/03/2026
Approval date [1] 319733 0
14/05/2026
Ethics approval number [1] 319733 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148222 0
Prof Jordan R. Hansford
Address 148222 0
Women’s and Children’s Hospital, 72 King William Road, North Adelaide SA 5006
Country 148222 0
Australia
Phone 148222 0
+61 8 8161 7000
Fax 148222 0
Email 148222 0
Contact person for public queries
Name 148223 0
Jordan R. Hansford
Address 148223 0
Women’s and Children’s Hospital, 72 King William Road, North Adelaide SA 5006
Country 148223 0
Australia
Phone 148223 0
+61 8 8161 7000
Fax 148223 0
Email 148223 0
Contact person for scientific queries
Name 148224 0
Brandon Wainwright
Address 148224 0
Frazer Institute, University of Queensland, St Lucia QLD 4072
Country 148224 0
Australia
Phone 148224 0
+61 7 3365 1111
Fax 148224 0
Email 148224 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.